Description

Simple

Clinical

Overview

Candoxatril is the orally-active prodrug of candoxatrilat (UK-73967), a potent neutral endopeptidase (NEP) inhibitor.

Pharmacology

Indication

Information currently not available.

Pharmacodynamic

Information currently not available.

Mechanism of action

Neutral endopeptidase inhibitors such as Candoxatril have a dual mechanism of action. They inhibit two metalloprotease enzymes, neutral endopeptidase and ACE, resulting in an increased availability of natriuretic peptides that exhibit vasodilatory effects and, possibly, tissue protective effects.

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Candoxatril
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
1-benzylimidazole
1-benzylimidazole may decrease the antihypertensive activities of Candoxatril.
2,5-Dimethoxy-4-ethylamphetamine
2,5-Dimethoxy-4-ethylamphetamine may decrease the antihypertensive activities of Candoxatril.
2,5-Dimethoxy-4-ethylthioamphetamine
2,5-Dimethoxy-4-ethylthioamphetamine may decrease the antihypertensive activities of Candoxatril.
4-Bromo-2,5-dimethoxyamphetamine
4-Bromo-2,5-dimethoxyamphetamine may decrease the antihypertensive activities of Candoxatril.
4-Methoxyamphetamine
4-Methoxyamphetamine may decrease the antihypertensive activities of Candoxatril.
5-methoxy-N,N-dimethyltryptamine
5-methoxy-N,N-dimethyltryptamine may decrease the antihypertensive activities of Candoxatril.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Candoxatril.
Abediterol
Abediterol may decrease the antihypertensive activities of Candoxatril.
Acebutolol
The therapeutic efficacy of Candoxatril can be increased when used in combination with Acebutolol.
Aceclofenac
The therapeutic efficacy of Candoxatril can be decreased when used in combination with Aceclofenac.
Acemetacin
The therapeutic efficacy of Candoxatril can be decreased when used in combination with Acemetacin.
Acepromazine
Acepromazine may decrease the antihypertensive activities of Candoxatril.
Adrafinil
Adrafinil may decrease the antihypertensive activities of Candoxatril.
Alclofenac
The therapeutic efficacy of Candoxatril can be decreased when used in combination with Alclofenac.
Aldesleukin
The therapeutic efficacy of Candoxatril can be increased when used in combination with Aldesleukin.
Alfentanil
Alfentanil may decrease the antihypertensive activities of Candoxatril.
Alfuzosin
Alfuzosin may increase the hypotensive activities of Candoxatril.
Aliskiren
The therapeutic efficacy of Candoxatril can be increased when used in combination with Aliskiren.
Alminoprofen
The therapeutic efficacy of Candoxatril can be decreased when used in combination with Alminoprofen.
Almotriptan
Almotriptan may decrease the antihypertensive activities of Candoxatril.